Arcus Biosciences (RCUS) Treasury Shares (2017 - 2025)
Arcus Biosciences (RCUS) posted quarterly Treasury Shares of $2.9 million for Q4 2025, up 31.82% year-over-year from $2.2 million in Q4 2024, and up 31.82% quarter-over-quarter from $2.2 million in Q4 2024.
Arcus Biosciences (RCUS) Treasury Shares (2017 - 2025) Analysis & Trends
Arcus Biosciences' Treasury Shares history runs 9 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- In Q4 2025, Treasury Shares rose 31.82% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (up 31.82% YoY), while the FY2025 annual figure was $2.9 million, up 31.82% from the prior year.
- Treasury Shares for Q4 2025 stood at $2.9 million, up from $2.2 million in the prior quarter.
- The five-year high for Treasury Shares was $2.9 million in Q4 2025, with the low at $1.1 million in Q4 2021.
- The 5-year median for Treasury Shares is $1.5 million (2023), against an average of $1.8 million.
- The sharpest annual moves came in 2021 and 2023: Treasury Shares soared 566.13% in 2021, then gained 15.38% in 2023.
- Arcus Biosciences' Treasury Shares stood at $1.1 million in 2021, then grew by 18.18% to $1.3 million in 2022, then rose by 15.38% to $1.5 million in 2023, then jumped by 46.67% to $2.2 million in 2024, then soared by 31.82% to $2.9 million in 2025.
- Business Quant data shows RCUS's Treasury Shares at $2.9 million in Q4 2025, $2.2 million in Q4 2024, and $1.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Dec 31, 2020 | 165,133.00 |
| Dec 31, 2020 | 165,133.00 |
| Sep 30, 2020 | 653,950.00 |
| Sep 30, 2020 | 653,950.00 |
| Dec 31, 2019 | 455,158.00 |
| Dec 31, 2019 | 455,158.00 |
| Sep 30, 2019 | 552,364.00 |
| Sep 30, 2019 | 552,364.00 |
| Jun 30, 2019 | 665,301.00 |
| Jun 30, 2019 | 665,301.00 |